Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × darolutamide × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 43 Breast 5 Head & Neck 2 Tumor-Agnostic 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gastrointestinal 1 Classical hematology 1

Conditions

Interventions

Surveys and Questionnaires 58 Blood Specimen Collection 43 Radiotherapy 35 Magnetic Resonance Spectroscopy 31 pembrolizumab 30 Nivolumab 28 Carboplatin 26 Radiosurgery 25 Gemcitabine 25 Bevacizumab 25 Standard of Care 24 Oxaliplatin 24 Capecitabine 24 Paclitaxel 23 Cisplatin 23 Fluorouracil 22 Interviews as Topic 21 Irinotecan 18 Everolimus 18 Erlotinib Hydrochloride 18 Methods 17 Docetaxel 16 Trastuzumab 15 Biopsy 15 Sorafenib 14 Educational Status 14 Cyclophosphamide 14 Ipilimumab 13 Specimen Handling 12 Radiation 12

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03314324 2025-04-17

ODENZA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡